A secondary analysis of how changes in pain interference relate to changes in health-related quality of life and physical function in heart failure.

Heart LungJul 6, 2026 (epub)
Clinical ResearchCardiologyOpen access

Asa B Smith, Miyeon Jung, Susan M Perkins et al.

✦ AI-curated · Sources linked

In 30 seconds

This secondary analysis of the MEMOIR-HF trial examined 240 heart failure patients to assess how changes in pain interference relate to changes in physical function and health-related quality of life (HRQoL). The study found that improvements in pain interference were significantly correlated with enhancements in both physical function and HRQoL, with F = 0.33, p = 0.038 for physical function and F = 1.62, p = 0.003 for HRQoL.

Key findings

  • Improvements in pain interference correlated with better physical function (F = 0.33, p = 0.038).
  • Improvements in pain interference were associated with enhanced HRQoL (F = 1.62, p = 0.003).
  • The study involved 240 heart failure participants assessed at multiple time points.

Why it matters

Understanding the relationship between pain interference and both physical function and HRQoL can help clinicians identify targets for intervention in heart failure patients, potentially improving overall patient outcomes.

Source

PubMed · PMID 42407429Free full text on PubMed Central

Published in Heart Lung. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.